All News

#ACR19 @rheumnow L20 head-to-head IXE vs ADA PSA 52wk trial: IXE shows significantly ⬆️ response than ADA for simultaneous ACR50 + PASI100 through Wk 52.TEAEs in 73.9% IXE &68.6% ADA pts. sAEs in 4.2% IXE&12.4% ADA pts, and d/c 2/2 AEs in 4.2% IXE & 7.4% ADApts; no deaths https://t.co/WeGdmu0vh6
Olga Petryna DrPetryna ( View Tweet)
#ACR19 RITAZAREM RCT rituxan vs imuran, AAV maintenance RTX superior to imuran w/HR 0.36 and relapse rate at 24 months (13% vs 38% imuran, NNT=4). Hypogam risk only 4% higher vs imuran (NNH~25) and non-severe infections similar Supports guideline recs from this AM! @RheumNow https://t.co/m9FkJ7d7I9
Mike Putman EBRheum ( View Tweet)
#ACR19 @RheumNow FINCH1 results for filgotinib in RA w/MTX inadequate response Good efficacy over PLBO for ACR50 at 24 wks (NNT~4), somewhat less impressive than UPA against TNF (NNT~20, not superior) Lower rates of HSV! Also, like UPA there is (as yet) no VTE signal https://t.co/1HjFgfXvlX
Mike Putman EBRheum ( View Tweet)
J Stone IgG4-RD pearl: If elevated at baseline the serum IgG4 is a good biomarker for IgG4-RD. If very high, IgG4, can be a marker for recurrent disease. Hypocomplementemia implies renal involvement. #ACR2018 @RheumNow

Maeve Gamble MaeveGamble ( View Tweet)

Ixekizumab is a high-affinity monoclonal antibody against interleukin-17A. In patients with psoriatic arthritis, ixekizumab was better than adalimumab in treating skin disease (PASI 100). Similar improvements in joint disease (ACR20/50/70). Dr. Josef Smolen #ACR19 @RheumNow https://t.co/BriY8o10Hq
Jonathan Hausmann MD hausmannMD ( View Tweet)
In patients with Sjogren's, Ianalumab, a dual-mode of action biologic combining BAFF receptor inhibition with B cell depletion, showed significant response in ESSDAI, a disease activity index, but did not seem to improve most PROs such as fatigue #ACR19 @RheumNow https://t.co/l5UFwOjt2C
Jonathan Hausmann MD hausmannMD ( View Tweet)
Abstr# 2440: Strong association between psoriatic arthritis and osteoporosis (45%) and osteopenia (13%). A good reminder to screen these patients to avoid complications of these additional comorbidities. #ACR19 @RheumNow https://t.co/0RvJtYCYJl
Dr. Paul Sufka psufka ( View Tweet)
Abstr# 2137: Patient with metastatic melanoma who develop PD-1 inhibitor related inflammatory arthritis have significantly improved survival. Although checkpoint inibitors are associated with autoimmune side effects, often suggests a better cancer prognosis. #ACR19 @RheumNow https://t.co/geTUO2yLJX
Dr. Paul Sufka psufka ( View Tweet)
It was such a pleasure to interview ACR Master Dr. John Reveille! He spoke about how the field has changed, what he looks forward to at #ACR19, and he even gave us a preview of his Hench lecture! @rheumnow @UTHealth https://t.co/JwIOWmBA4x via @YouTube

Links:

Kanika Monga, MD DrKanikaMonga ( View Tweet)

SLE has high work disability. Interestingly work disability was not high in some organ systems such as renal but mild GN or CRF may not be symptomatic. Fibromyalgia, low education, low SED and older age increase work disability ACR219 @RheumNow abstr 1578 https://t.co/DdHgluRPIV
Janet Pope Janetbirdope ( View Tweet)
Anifrolumab, a type I IFN receptor antagonist, was effective in patients with SLE to increase BICLA response versus placebo. Results of the TULIP-2 trial. #ACR19 @RheumNow

Jonathan Hausmann MD hausmannMD ( View Tweet)

J Stone GCA pearls: Dry cough can be a symptom of occult GCA. Jaw claudication comes on quickly. Predicts +ve TAB. Tongue ulcers in GCA occur on the lat. part of the mid tongue. This is a watershed area for blood supply. Strawberry gums can be seen in GCA. #ACR19 @RheumNow

Maeve Gamble MaeveGamble ( View Tweet)

“TULIP-2 was a positive phase 3 trial in lupus, and there haven’t been many times before that those words have been spoken” - @EricFMorand Anifrolumab in mod-severe SLE #ACR19 L17 @RheumNow @US_FDA https://t.co/8lqBmaWHW0
David Liew drdavidliew ( View Tweet)
Telitacicept is a recombinant fusion protein with the extracellular domain of TACI and the FC domain of human IgG1. #ACR19 @RheumNow

Jonathan Hausmann MD hausmannMD ( View Tweet)

Are urine metabolomics able to differentiate between healthy controls (HC), RA, SLE, & SpA? Small study of prevalent pts showed SLE and RA metabolomics v diff from controls and SpA. Don't know if diff early or pre clinical disease #ACR19 @RheumNow abstr 2127 https://t.co/mBh5nxRcqk
Janet Pope Janetbirdope ( View Tweet)
5-year effectiveness of TNFi in patients with early axSpA shown, male gender, HLAB27 positive and presence of at least one objective sign of inflammation or structural damage are more frequently associated with effectiveness #2776 by Molto #ACR19 @RheumNow

Dr. Antoni Chan synovialjoints ( View Tweet)

What dose of MTX do you usually start with in a newly diagnosed rheumatoid arthritis patient? #ACR19 @RheumNow

Philip Robinson philipcrobinson ( View Tweet)

@_connectedcare @RheumNow @ACRheum My pearls (so far) 1. Use vitamin A to reduce SEs w MTX 2. Try doxycycline for refractory calcinosis in scleroderma 3. Use MTX with pegloticase to reduce infusion reactions 4. Anti-IL17 has activity in nr-axSpA 5. Patients think opiates are more effective than SNRIs or TCAs in FM

Philip Robinson philipcrobinson ( View Tweet)

@RheumNow #ACR19 #acrbest abs2470 ⬆️serum calprotectin in PsA pts associated w/presence of carotid plaque, ⬆️intima-media thickness & ⬆️CRP. potential novel bio marker of CV disease in PsA https://t.co/ech3Ll8Nka
Olga Petryna DrPetryna ( View Tweet)
As I leave #acr19, time to reflect. My goal is to uncover pearls that change what I do in my next few clinics. 3 this time. How many such pearls did you find? @RheumNow @ACRheum

Dr Irwin Lim _connectedcare ( View Tweet)

×